GET DAILY SIGNALSSpero Therapeutics (SPRO) Holds Near $1.14 Amid Pipeline Transition
Key Takeaways
- Spero Therapeutics (SPRO) traded near $1.14 in late October 2026, essentially flat over the trailing 30 days despite a sharp multi-month pullback from earlier-2026 highs.
- The stock sits near the low end of its 52-week range of $1.04 to $3.08, with a market capitalization around $66 million.
- The U.S. Food and Drug Administration approved Utebzi (tebipenem HBr) in June 2026, the first and only oral carbapenem antibiotic for complicated urinary tract infections including pyelonephritis.
- GSK holds global commercialization rights to Utebzi, providing potential milestone and royalty upside for Spero.
- Spero pivoted its pipeline toward immunology by in-licensing SP001, an anti-CD40L antibody targeting IgG4-related disease and Sjögren's disease.
- A $105 million royalty-based financing extended the company's cash runway into the second half of 2029.
- For additional detail, explore Spero's Price Targets, Earnings, and Forecast pages.
Current Market Snapshot
Spero Therapeutics shares have settled into a low-single-digit trading range in recent weeks, closing near $1.14 in late October 2026. Over the trailing 30 days, the stock has been roughly flat, with intraday swings failing to produce a sustained directional move of 10% or more in either direction. This stability follows a considerably weaker stretch for the shares, which have retreated from levels above $2 earlier in 2026 and now trade toward the bottom of a 52-week range spanning $1.04 to $3.08. With a modest market capitalization near $66 million and thin average volume, the stock remains sensitive to clinical, regulatory, and financing headlines rather than broad biotech sector rotation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Spero Therapeutics (SPRO) Business Overview and Competitive Position
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and, more recently, rare immune-mediated diseases. The company's lead asset, Utebzi (tebipenem HBr), is an oral carbapenem antibiotic approved in June 2026 for treating complicated urinary tract infections, including pyelonephritis, in adult patients with limited alternative oral treatment options. It represents the first and only oral carbapenem approved in the United States, addressing a significant gap for patients who would otherwise require intravenous therapy.
Following the Utebzi approval, Spero broadened its strategy into immunology by in-licensing SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody, from Innovent Biologics. The company intends to advance SP001 into a Phase 2 trial for IgG4-related disease, with initiation planned for the second quarter of 2027. Spero's commercialization leverage is tied to its partnership with GSK, which holds global rights to Utebzi, while a non-dilutive royalty financing has strengthened the company's balance sheet and extended its operating runway.
Recent Developments Driving SPRO
Spero's recent narrative has been defined by execution on its regulatory and financing milestones rather than a single market-moving catalyst. The June 2026 FDA approval of Utebzi validated a clinical program that had been advancing for years, but the immediate share reaction was muted by a broader decline that had already priced in much of the regulatory outcome. In July, the company announced the in-licensing of SP001 and a $105 million, non-dilutive royalty financing backed by Healthcare Royalty, an affiliate of KKR, which extended its cash runway into the second half of 2029. The addition of a chief medical officer with rheumatology and immunology expertise reinforced the pivot toward immune-mediated disease.
Analyst coverage remains limited but constructive, with a consensus rating of Buy and an average one-year price target near $5.00, according to S&P Global data. Even so, the stock's multi-month downtrend reflects investor caution around a small-cap biotech transitioning between therapeutic franchises, with near-term revenue expected to be modest as GSK begins its U.S. launch of Utebzi.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary drivers for Spero will be the U.S. launch trajectory of Utebzi under GSK's commercialization, the progression of SP001 toward its planned Phase 2 study in IgG4-related disease, and the company's disciplined use of its extended cash runway. Investors will also monitor quarterly financial disclosures, including the next scheduled earnings report, for updates on milestone payments, royalty recognition, and operating expenses. Macroeconomic and sector-level conditions, including biotech financing appetite and interest-rate sensitivity among development-stage companies, remain relevant but secondary to company-specific execution. As with any clinical-stage biopharmaceutical, regulatory, clinical, and partnership outcomes carry meaningful risk and should be weighed carefully alongside any forward-looking outlook. From what I see, this is important because execution on these fronts will likely determine whether the stock can move beyond its current range.
Using Tickeron’s Trending AI Robots for Perspective
I often review Tickeron’s Trending AI Robots when evaluating small-cap names like SPRO. The page highlights top-performing AI-driven bots across various strategies and timeframes, giving a data-backed view of momentum signals without replacing fundamental analysis. It helps me cross-check how automated models are responding to recent developments in volatile biotech names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SPRO's Stochastic Oscillator descending into oversold zone
The Stochastic Oscillator for SPRO moved into oversold territory on October 26, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +10.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in 151 of 206 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for SPRO moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In 77 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
SPRO moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SPRO crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
SPRO broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SPRO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.502) is normal, around the industry mean (3.037). P/E Ratio (8.143) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (1.550) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapies for the treatment of resistant bacterial infections
Industry Biotechnology
Advertisement